DigestRedComo funciona
Red
/
Empresas
Bi
No verificado

Biogen Inc.

Sobre qué escribimos

Anuncios brevesBiotecnologíaFinanzasGestión empresarial/Administración de EmpresasMedicina Salud Bienestar

71 Comunicados de prensa

Ver todos los comunicados de prensa
06/08/2026
Biotecnología
Medicina Salud Bienestar
Biogen Completes Acquisition of RayThera Inc.
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0
15/07/2026
Biotecnología
Biogen Appoints Michael J. Parini as Chief Legal Officer
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0
29/06/2026
Biotecnología
Medicina Salud Bienestar
Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0
17/06/2026
Biotecnología
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0
04/06/2026
Biotecnología
Anuncios breves
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0
03/06/2026
Biotecnología
Medicina Salud Bienestar
Anuncios breves
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0
14/05/2026
Biotecnología
Medicina Salud Bienestar
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0
20/04/2026
Biotecnología
Gestión empresarial/Administración de Empresas
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0
31/03/2026
Biotecnología
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0
30/03/2026
Biotecnología
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
Fuente
Biogen Inc.
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0